Literature DB >> 9624601

Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration.

A Colao1, R Pivonello, D Ferone, G La Tessa, A Faggiano, G Facciolli, C Di Somma, B Merola, G Lombardi.   

Abstract

Atrial natriuretic factor (ANF) was suggested to be involved as neurohormone in the modulation of hypothalamus-pituitary-adrenal axis in humans. However, this role is still controversial and widely discussed. In order to evaluate whether ANF is secreted in the hypothalamus-pituitary system in humans, plasma ANF concentrations were assayed in samples collected in the inferior petrosal sinus (IPS) blood of patients subjected to IPS sampling for diagnostic purposes or neurosurgical indications. In this retrospective study were included 22 patients: 10 with Cushing's disease (CD) and 12 patients with GH or PRL-secreting pituitary adenoma, used as control group. In the patients with CD, plasma ANF concentration was also assayed after CRH test (hCRH 100 micrograms as i.v. bolus with blood samples after 5, 10 and 15 min). Both in patients with CD and in patients with GH- or PRL-secreting pituitary adenoma, no significant difference was found in plasma ANF levels between IPS ipsilateral (13.0 +/- 1.5 and 12.2 +/- 1.2 pmol/l) or controlateral (13.0 +/- 1.6 and 12.2 +/- 1.4 pmol/l) to the adenoma and peripheral blood (14.2 +/- 2.0 and 13.7 +/- 1.5 pmol/l, respectively). Similarly, no difference was found between the IPS ipsilateral and controlateral to the adenoma in both groups of patients. In patients with CD, CRH administration induced a significant increase of ACTH levels (periphery: 34.9 +/- 6.2 vs 11.5 +/- 2.3 pmol/l, p < 0.05) but it did not induce any significant change of plasma ANF levels (14.0 +/- 2.0 vs 13.4 +/- 1.4 pmol/l in the ipsilateral IPS and 13.4 +/- 1.6 vs 13.4 +/- 1.5 pmol/l in the ipsilateral IPS and 13.4 +/- 1.6 vs 13.4 +/- 1.5 pmol/l in the contralateral IPS). In conclusion, the lack of ANF concentration gradient between IPS and peripheral blood, the lack of any difference in ANF concentrations between patients with CD and acromegalics or hyperprolactinemics and the absence of ANF response to CRH administration do not support the hypothesis of a role for ANF as neurohormone involved in the hypothalamus-pituitary control and particularly in the hypothalamus-pituitary-adrenal axis modulation in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624601     DOI: 10.1007/BF03347312

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies.

Authors:  B Merola; S Longobardi; A Colao; C Di Somma; D Ferone; F Di Rella; R Pivonello; V Covelli; L Annunziato; G Lombardi
Journal:  Neuroendocrinology       Date:  1996-11       Impact factor: 4.914

2.  Atrial natriuretic peptide in physiological doses does not inhibit the ACTH or cortisol response to corticotrophin-releasing hormone-41 in normal human subjects.

Authors:  E Ur; M Faria; S Tsagarakis; J V Anderson; G M Besser; A Grossman
Journal:  J Endocrinol       Date:  1991-10       Impact factor: 4.286

3.  Hormonal gradients between inferior petrosal sinuses in various pituitary diseases.

Authors:  B Merola; A Colao; E Rossi; G La Tessa; R Spaziante; G Lombardi
Journal:  Acta Endocrinol (Copenh)       Date:  1992-05

Review 4.  Atrial natriuretic peptide in brain and pituitary gland.

Authors:  J Gutkowska; J Antunes-Rodrigues; S M McCann
Journal:  Physiol Rev       Date:  1997-04       Impact factor: 37.312

5.  Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues.

Authors:  A L Gerbes; L Dagnino; T Nguyen; M Nemer
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

6.  Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome.

Authors:  E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

7.  Atrial natriuretic factor reduces vasopressin and angiotensin II but not the ACTH response to acute hypoglycaemic stress in normal men.

Authors:  G A Wittert; E A Espiner; A M Richards; R A Donald; J H Livesey; T G Yandle
Journal:  Clin Endocrinol (Oxf)       Date:  1993-02       Impact factor: 3.478

8.  Effect of atrial natriuretic factor infusion on basal and CRH-stimulated ACTH, cortisol and aldosterone levels in patients with Cushing's or Addison's disease.

Authors:  B Ambrosi; C Sala; D Bochicchio; P Colombo; G Gazzano; C Fadin; A Morganti; G Faglia
Journal:  Clin Endocrinol (Oxf)       Date:  1994-05       Impact factor: 3.478

9.  Alpha-melanocyte-stimulating hormone is present in the inferior petrosal sinuses in patients with Cushing's disease.

Authors:  A Colao; B Merola; M Cataldi; G La Tessa; F Boudouresque; C Oliver; G Di Renzo; L Annunziato; G Lombardi
Journal:  Neuroendocrinology       Date:  1993-08       Impact factor: 4.914

10.  Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man.

Authors:  M Kellner; K Wiedemann; F Holsboer
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.